Researchers have invented a cheap, portable, microchip-based test for diagnosing type-1 diabetes that could speed up diagnosis and enable studies of how the disease develops.
An inexpensive, portable, microchip-based test for diagnosing type-1 diabetes could improve patient care worldwide and help researchers better understand the disease, according to the device’s inventors at the Stanford University School of Medicine.
Described in a paper published online July 13 inNature Medicine, the test employs nanotechnology to detect type-1 diabetes outside hospital settings. The handheld microchips distinguish between the two main forms of diabetes mellitus, which are both characterized by high blood-sugar levels but have different causes and treatments. Until now, making the distinction has required a slow, expensive test available only in sophisticated health-care settings. The researchers are seeking Food and Drug Administration approval of the device.
“With the new test, not only do we anticipate being able to diagnose diabetes more efficiently and more broadly, we will also understand diabetes better — both the natural history and how new therapies impact the body,” said Brian Feldman, MD, PhD, assistant professor of pediatric endocrinology and the Bechtel Endowed Faculty Scholar in Pediatric Translational Medicine. Feldman, the senior author of the paper, is also a pediatric endocrinologist at Lucile Packard Children’s Hospital Stanford.
Better testing is needed because recent changes in who gets each form of the disease have made it risky to categorize patients based on their age, ethnicity or weight, as was common in the past, and also because of growing evidence that early, aggressive treatment of type-1 diabetes improves patients’ long-term prognoses.
The Latest on: Diabetes
via Google News
The Latest on: Diabetes
- Women with diabetes less likely to receive comprehensive cardiovascular prevention than men, international study findson September 26, 2021 at 4:12 pm
Women with type 2 diabetes and cardiovascular disease (CVD), or at high risk of developing CVD, are less likely to reach recommended treatment targets than men, according to an international study ...
- Millions of diabetes tests missed in first six months of pandemic – researchon September 26, 2021 at 3:33 pm
The Benchmarking Partnership released estimates on missed blood tests based on data collected from six UK testing centres.
- UK study estimates 2.5 million diagnostic tests for diabetes missed or delayed during lockdownon September 26, 2021 at 3:03 pm
New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD), held online this year (27 Sept-1 Oct), finds that the COVID-19 response has left more ...
- Gender Affirming Hormone Therapy and Diabeteson September 26, 2021 at 1:34 pm
Eating a healthy diet is the cornerstone of living well with diabetes and preventing complications. Unfortunately, transgender individuals on gender-affirming hormone therapy (GAHT) are at increased ...
- Ozone exposure link to the development of type 2 diabeteson September 24, 2021 at 10:29 am
Older Californians who live in communities with poor air quality, even those who engage—as recommended—in physical activities but do so outdoors, have a higher risk of Type 2 diabetes, a complex and ...
- Study: Insulin resistance doubles risk for depression, even without diabeteson September 24, 2021 at 12:05 am
Insulin resistance can make you more than twice as likely to develop major depression, even if you haven't developed full-blown diabetes, a new study reports.
- Diabetes drug may help women with preeclampsia prolong pregnancyon September 23, 2021 at 10:05 pm
Metformin, a commonly prescribed diabetes drug, may help stave off preterm birth among women who develop pregnancy-related high blood pressure.
- EASD: Precision in Diabetes Management and Impact of COVID-19on September 23, 2021 at 7:29 am
The European Association for the Study of Diabetes annual meeting will feature precision medicine sessions, a consensus statement on type 1 diabetes care, and new data on the twincretin tirzepatide.
- Diabetes targets would cost more but the impact would be worth it: here’s howon September 23, 2021 at 3:00 am
Targets for diabetes would improve healthy lives, reduce deaths, and be cost effective. But they should not be for managing diabetes alone; they must include treating hypertension.
- Prenome could help pregnant women better predict and manage gestational diabeteson September 22, 2021 at 10:01 am
Stevie Cline, the co-founder of Prenome, is tired of how invasive diagnostic processes are for women, even with modern technology and broader healthcare advancements. Prenome, going through TechCrunch ...
via Bing News